S

Sendai Kousei Hospital | Clinical Trial Management Office

Research site
(Unclaimed)
Location
4-15, Hirosemachi, Aoba-ku, Sendai, Miyagi, Japan

Site insights

Top conditions

Top treatments

Brigatinib
Patritumab
Zipalertinib
Crizotinib
Pembrolizumab
Repotrectinib
Alectinib
Tegafur-Uracil
Mobocertinib
Ramucirumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 39 total trials

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criter...

Active, not recruiting
ALK-positive Advanced NSCLC
Drug: Brigatinib

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Crizotinib
Drug: Lorlatinib

This study is in 2 parts. Different participants will take part in the 1st and 2nd parts of the study.The main aim of the 1st part of the study is to...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Mobocertinib

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combinat...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Drug: Gefitinib
Drug: Osimertinib

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Crizotinib
Drug: Repotrectinib

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this stu...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: TAK-788

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR...

Enrolling
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Drug: TAS6417

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling
Atrial Fibrillation
Stroke
Drug: Non-Vitamin K Oral Antagonists
Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms con...

Enrolling
Relapsed Small Cell Lung Cancer
Drug: Irinotecan
Drug: Lurbinectedin

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Cisplatin
Drug: Datopotamab Deruxtecan

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platin...

Active, not recruiting
Nonsquamous Non-small Cell Lung Cancer
EGFR L858R
Drug: Platinum-based chemotherapy
Drug: Patritumab Deruxtecan

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or d...

Active, not recruiting
Aortic Valve Stenosis
Device: Surgical Aortic Valve Replacement (SAVR)
Device: Medtronic Transcatheter Aortic Valve Replacement Systems

To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in patients with severe, calcific aortic stenosis w...

Active, not recruiting
Aortic Stenosis
Device: SAPIEN 3 THV
Procedure: SAVR

This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Hea...

Enrolling
Aortic Valve Stenosis
Aortic Stenosis, Calcific
Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy...

Enrolling
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Drug: TAS6417

This is a prospective, single-arm, multi-center study designed to evaluate the safety and efficacy of the Orbital Atherectomy System (OAS) for the tr...

Enrolling
Peripheral Artery Disease
Device: CSI Peripheral Orbital Atherectomy System (OAS)

A Randomized Trial Comparing the Agent Paclitaxel-Coated PTCA Balloon Catheter vs SeQuent Please Drug Eluting Balloon Catheter for the Treatment of a...

Active, not recruiting
Coronary Artery Disease
Device: SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel
Device: Device: Paclitaxel-Coated PTCA Balloon Catheter

Trial sponsors

Abbott logo
AbbVie logo
Chugai Pharmaceutical logo
Daiichi Sankyo logo
Takeda logo
Boston Scientific logo
Edwards Lifesciences logo
Taiho Pharma logo
A
Boston Scientific logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems